Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colopeg is a polyethylene glycol (PEG)-based osmotic laxative used for bowel cleansing prior to colonoscopy, colonic surgery, or radiological examinations. Developed by Norgine, it is a high-volume (typically 4-liter) preparation consisting of macrogol 3350 combined with a balanced mixture of electrolytes, including sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride. The mechanism of action involves the osmotic effect of macrogol, which binds water in the intestinal lumen, increasing stool volume and stimulating peristalsis to effectively clear the colon. The inclusion of electrolytes helps to maintain the patient's fluid and electrolyte balance during the lavage process. It is administered orally as a solution reconstituted from powder sachets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Colopeg.